1. A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Bladder Cancer Overview

4. History of Immunotherapy in Bladder Cancer: BCG

5. Impact of the Immune System on Outcomes in Muscle-Invasive Disease

6. Bladder Cancer Has High Mutation Burden

7. PD-1 Pathway

8. PD-1 and PD-L1 Inhibition

9. PD-1/PD-L1 Inhibition in Platinum-Pretreated Patients

10. IMvigor210: Phase 2 Trial of Atezolizumab

11. Tumor Reduction With Atezolizumab

12. Duration of Response to Atezolizumab

13. Clinical Benefit From Atezolizumab

14. Median Progression-Free Survival With Atezolizumab

15. Overall Survival With Atezolizumab

16. CheckMate 275: Phase 2 Trial of Nivolumab

17. Antitumor Activity of Nivolumab

18. Overall Survival With Nivolumab

19. KEYNOTE-045: Phase 3 Trial of Pembrolizumab

20. Overall Survival: Pembrolizumab vs Standard Chemotherapy

21. Progression-Free Survival: Pembrolizumab vs Chemotherapy

22. Overall Survival: CPS ≥10%

23. Confirmed Overall Response Rate With Pembrolizumab

24. PD-1 Inhibition in Treatment-Naive Patients

25. IMvigor210 Study: Cohort 1 from the Phase 2 Atezolizumab Study

26. IMvigor210: Cohort 1 Response Rate

27. IMvigor210: Cohort 1 Overall Survival

28. KEYNOTE-052: Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Cancer

29. KEYNOTE-052: Overall Response Rate

30. KEYNOTE-052: Duration of Response

31. Adverse Events

32. Current Status of Systemic Therapy for Bladder Cancer

33. Role of PD-L1 Immunohistochemical Staining

34. Role of PD-L1 Immunohistochemical Staining (cont)

35. Mutation Load and Overall Response

36. Biomarkers Beyond PD-L1: Mutation Load and OS

37. Biomarkers Beyond PD-L1: Expression Subtype

38. Molecular Subtype, 25-Gene Interferon-γ Signature, and Response to Nivolumab

39. Resistance to Checkpoint Inhibition

40. Summary

41. Abbreviations

42. Abbreviations (cont)